Format

Send to

Choose Destination
J Hepatol. 2011 Apr;54(4):830-4. doi: 10.1016/j.jhep.2010.10.013. Epub 2010 Nov 9.

Potential of immunotherapy for hepatocellular carcinoma.

Author information

1
Department of Medicine II, University of Freiburg, Hugstetter Strasse 55, D-79106 Freiburg, Germany.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with limited therapeutic options. Since HCC has been shown to be immunogenic, T cell-based immunotherapy is considered a promising treatment. In this review, we summarize current knowledge of T cell responses against tumour-associated antigens, as well as the mechanisms underlying the poor quality of these responses in patients with HCC. Insights into these important aspects of HCC immunology are crucial for the further development of novel immunotherapies.

PMID:
21145836
DOI:
10.1016/j.jhep.2010.10.013
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center